Rein Therapeutics (RNTX)
NASDAQ:RNTX
Want to see RNTX full AI Analyst Report?
RNTX Stock Chart & Stats
$1.26
--
Market closed
$1.26
--
Day’s Range― - ―
52-Week Range$0.89 - $2.18
Previous CloseN/A
VolumeN/A
Average Volume (3M)228.95K
Market Cap
$81.94M
Enterprise Value$31.51M
Total Cash (Recent Filing)$4.45M
Total Debt (Recent Filing)$4.92M
Price to Earnings (P/E)―
Beta1.33
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding85,539,030
10 Day Avg. Volume262,542
30 Day Avg. Volume228,948
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.74
Price to Sales (P/S)0.00
P/FCF Ratio-1.52
Enterprise Value/Market Cap0.38
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.43
Forecast
1Y Price Target
$8.00Price Target Upside534.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Pulmonary Clinical-stage PipelineA narrow, disease-focused clinical strategy concentrates scientific, regulatory, and commercial efforts on pulmonary indications. This specialization can yield durable advantages in trial design expertise, investigator relationships, and later-stage partnering or licensing opportunities within the pulmonary market over multiple years.
Modest Financial LeverageLow absolute debt relative to equity provides structural financial flexibility and reduces bankruptcy risk versus highly levered peers. For a cash-burning clinical-stage biotech, modest debt preserves ability to access capital and prioritize R&D spending without heavy interest burdens over the medium term.
Material Equity Financing Extends RunwayA $50M offering materially extends operating runway into 2028, lowering immediate refinancing risk and allowing continued Phase 2 development. The transaction and investor lock-up/warrant arrangements create more predictable capital structure and let management execute clinical milestones with less near-term liquidity distraction.
Bears Say
No Revenue And Large Net LossesAbsence of product revenue and persistent, substantial net losses mean value creation depends solely on clinical progress or external deals. This structural reliance on milestones and financing increases execution risk and makes long-term sustainability contingent on successful trials or partner transactions.
Negative Operating And Free Cash FlowConsistent negative operating and free cash flow confirm ongoing cash burn and the need for recurrent capital raises. Over the medium term this pressures management to dilute shareholders or accept less favorable financing terms if clinical timelines slip or costs rise, raising structural financing risk.
Eroding Equity And Dilution RisksA shrinking equity base over prior years indicates cumulative losses and prior financings that dilute existing holders. Continued burn and recent large equity issuance materially raise dilution risk and reduce shareholder capital resilience, making future financing terms and dilution a persistent structural concern.
Rein Therapeutics News
RNTX FAQ
What was Rein Therapeutics’s price range in the past 12 months?
Rein Therapeutics lowest stock price was $0.89 and its highest was $2.18 in the past 12 months.
What is Rein Therapeutics’s market cap?
Rein Therapeutics’s market cap is $81.94M.
When is Rein Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Rein Therapeutics’s earnings last quarter?
Currently, no data Available
Is Rein Therapeutics overvalued?
According to Wall Street analysts Rein Therapeutics’s price is currently Undervalued.
Does Rein Therapeutics pay dividends?
Rein Therapeutics does not currently pay dividends.
What is Rein Therapeutics’s EPS estimate?
Rein Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Rein Therapeutics have?
Rein Therapeutics has 85,539,030 shares outstanding.
What happened to Rein Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Rein Therapeutics?
Currently, no hedge funds are holding shares in RNTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rein Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (534.92% Upside)
$8.00 (534.92% Upside)
Insider Transactions
Bought Shares
Worth $74.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.1%
Last 30 Days ▼ 7.8%
Last 30 Days ▼ 7.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.80%
12-Months-Change
Fundamentals
Return on Equity
-258.45%
Trailing 12-Months
Asset Growth
-54.38%
Trailing 12-Months
Company Description
Rein Therapeutics
Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating peptide. This compound works by disrupting the harmful interaction between the p53 suppressor proteins, MDM2 and MDMX, and the vital p53 tumor suppressor. Its goal is to reactivate the natural tumor-suppressing pathways in cancers where the p53 gene is still functional, or "wild-type." The organization was founded on August 6, 2001, by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky, and its main corporate offices are situated in Austin, Texas.
RNTX Stock 12 Month Forecast
Average Price Target
$8.00
▲(534.92% Upside)
Technical Analysis
Ownership Overview
1.78% Insiders
1.38% Mutual Funds
11.00% Other Institutional Investors
84.50% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---